Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
Leap Therapeutics To Present Updated Data From The DisTinGuish Study Of DKN-01 Plus Tislelizumab And Preclinical Data In Colorectal Cancer Models At The Society of Immunotherapy for Cancer Annual Meeting
CAMBRIDGE, Mass., Oct. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday’s Mid-Day Session
Gainers
Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
Raymond James Maintains Outperform on Leap Therapeutics, Raises Price Target to $3.5
Raymond James analyst Steven Seedhouse maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and raises the price target from $3 to $3.5.
Raymond James Maintains Outperform on Leap Therapeutics, Lowers Price Target to $3
Raymond James analyst Steven Seedhouse maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price target from $4 to $3.